Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07003828

Hemodialysis-Induced Renal Perfusion Decline: Unraveling the Pathophysiological Mechanisms Linking Intradialytic Circulatory Stress to Residual Renal Function Loss

Residual renal function (RRF) plays a critical role in quality of life and survival in hemodialysis (HD) patients but characteristically declines after the initiation of HD. Owing to incomplete understanding of the pathophysiology underlying RRF decline, protective strategies remain limited. The aim of this study was to characterize the changes in renal perfusion in incident HD patients with preserved RRF during dialysis sessions and to provide new strategies for RRF preservation.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

End-Stage Renal Disease Requiring Haemodialysis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

the First Medical Center of Chinese PLA General Hospital

Beijing, 100853, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) adult patients with end-stage renal disease (ESRD) within 3 months of commencing HD; (2) preserved RRF defined as urinary output >500 mL/24 h or eGFR ≥3 mL/min/1.73 m²

Exclusion criteria

  • (1) known allergy to sulfur hexafluoride microbubbles (SonoVue®) microbubbles; (2) vascular access dysfunction; (3) combined peritoneal dialysis; (4)severe cardiopulmonary disease; (5) active infection or malignancy; (6) communicable diseases; (7) pregnancy or breastfeeding; (8) participation in other clinical trials.

Treatment and study plan

CEUS examinations

Diagnostic Test

CEUS examinations were performed at three predetermined time points during each HD session: immediately before, 3 hours after HD initiation, and 15 minutes post-dialysis.

Primary outcomes

  1. Renal perfusion

    Time frame: at three time points during the HD session: pre-dialysis baseline, intradialytic phase (3 hours post-initiation)

    Renal perfusion was quantified using the CEUS-assessed perfusion index (PI). The primary outcome measure was the PI.

Sponsors and collaborators

Lead sponsor

Yuanjun Yang

Other

Registry information

Acronym: HD-RPD

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jun 4, 2025
Registry last updated
Jun 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.